PURE Bioscience Reports Fourth Quarter and Fiscal Year 2010 Results: Loss Per Share of $0.20

PURE Bioscience

, creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fourth quarter and fiscal year ended July 31, 2010 (“Fiscal 2010”). Fiscal 2010 total revenues of $1,436,000, including licensing fees, increased by 97% over revenues of $728,300 in the year ended July 31, 2009 (“Fiscal 2009”). The net loss for Fiscal 2010 was $6,760,300, or $0.20 per share, compared with a loss of $7,067,300, or $0.23 per share, in Fiscal 2009.